2025
P112 Cytokine driven disease and epigenetic heterogeneity in rheumatoid arthritis
Hughes S, Costa D, Soria A, Hill D, Figueras A, Scott R, Dimonte S, Monaco F, Jenkins R, Twohig J, Guy C, Cossins B, Andrews R, Szomolay B, Choy E, Vinh N, Lewis M, Jenkins B, Turner S, Tiganis T, Williams N, Yu H, Pitzalis C, Jones G, Jones S. P112 Cytokine driven disease and epigenetic heterogeneity in rheumatoid arthritis. Rheumatology 2025, 64: keaf142.152. DOI: 10.1093/rheumatology/keaf142.152.Peer-Reviewed Original ResearchEctopic lymphoid-like structuresAntigen-induced arthritisRNA-seqTransposase-accessible chromatin (ATAC)-seqRheumatoid arthritisChromatin immunoprecipitation (ChIP)-seqTreatment of immune-mediated inflammatory diseasesClinical response to therapyCytokine signalingSynovial biopsiesImmune-mediated inflammatory diseasesSmall-needle biopsiesLymphoid-like structuresResponse to therapyNature of pathologyWT miceEpigenetic heterogeneityNeedle biopsyTargeting cytokine signallingGenomic signaturesImmune pathologyNGS methodSTAT3 activationTranscription factorsEpigenetic regulation
2012
The Eye as a Target Organ for Stem Cell Therapy
Fields M, Hwang J, Gong J, Cai H, Del Priore L. The Eye as a Target Organ for Stem Cell Therapy. Stem Cell Biology And Regenerative Medicine 2012, 1-29. DOI: 10.1007/978-1-4614-5493-9_1.Peer-Reviewed Original ResearchAge-related macular degenerationRetinal pigment epitheliumRetinal degenerative diseasesStem cell therapyCell therapyRetinitis pigmentosaDegenerative diseasesCurrent clinical trialsPromising therapeutic optionNature of pathologyViable clinical optionReplacement therapyTherapeutic optionsClinical trialsCell replacement therapyMacular degenerationRetinal disordersCellular disarrayPigment epitheliumTarget organsPharmaceutical treatmentClinical optionProgressive cellular dysfunctionRetinal degenerationTherapeutic interventions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply